Latest Lung Imaging News

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

4DMedical secures a key clinical adoption milestone as the University of Miami begins using its CT – VQ™ respiratory imaging technology, following Stanford’s lead. Meanwhile, Lahey Hospital inks a two-year deal for IQ-UIP™, underscoring growing traction in US academic medical centers.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.

4DMedical Limited has secured FDA clearance for CT – VQ™, the first non-contrast CT-based ventilation-perfusion imaging technology, promising to transform lung diagnostics by replacing traditional nuclear scans.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.